Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0216
Abstract: The next-generation antiandrogen drugs such as enzalutamide and abiraterone extend survival times and improve quality of life in patients with advanced prostate cancer. However, resistance to both drugs occurs frequently through mechanisms which are incompletely… read more here.
Keywords: wnt5a fzd2; wnt5a sirna; prostate cancer; cancer ... See more keywords
Abstract 3069: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3069
Abstract: Introduction and Objectives: Androgen receptor (AR) blockade using antiandrogens is a mainstay for the treatment of castration-resistant prostate cancer (CRPC). However, resistance to antiandrogens occurs unavoidably due to the escaping mechanisms of tumor cells that… read more here.
Keywords: prostate cancer; neural lineage; wnt5a fzd2; wnt5a ... See more keywords
Abstract B023: Targeting noncanonical Wnt5a signaling suppresses the neural lineage network and overcomes enzalutamide resistance in advanced prostate cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.prca2023-b023
Abstract: INTRODUCTION AND OBJECTIVES Androgen receptor (AR) blockade using antiandrogens is a mainstay for the treatment of castration-resistant prostate cancer (CRPC). However, resistance to antiandrogens occurs unavoidably due to the escaping mechanisms of tumor cells that… read more here.
Keywords: prostate cancer; neural lineage; wnt5a fzd2; wnt5a ... See more keywords